Stem Cell Clinic

CoRegen Appoints Edward J. Benz, M.D., to its Board of Directors

By Global News Feed

Dr. Benz, former president and chief executive officer of Dana-Farber Cancer Institute, joins CoRegen's Board of Directors, bringing more than three decades of expertise in oncology research and cancer care Dr. Benz, former president and chief executive officer of Dana-Farber Cancer Institute, joins CoRegen's Board of Directors, bringing more than three decades of expertise in oncology research and cancer care

Continue reading here:
CoRegen Appoints Edward J. Benz, M.D., to its Board of Directors

BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

By Global News Feed

SUNNYVALE, Calif., Nov. 16, 2023 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA] (the “Company”), a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the purchase and sale of 2,000,000 shares of the Company’s common stock at a purchase price of $0.65 per share of common stock in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about November 20, 2023, subject to the satisfaction of customary closing conditions.

View post:
BioCardia Announces $1.3 Million Registered Direct Offering of Common Stock Priced At-the-Market under Nasdaq Rules

Oxurion Receives EUR 1.0 Million under Amended Atlas Funding Program   Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Reach…

By Global News Feed

Leuven, BELGIUM, Boston, MA, US – November 16, 2023 – 7 pm CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, announced today that it has received EUR 1.0 million in funding under the Subscription Agreement with Atlas Special Opportunities LLC (“Atlas”).

Continued here:
Oxurion Receives EUR 1.0 Million under Amended Atlas Funding Program   Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Reach...

Better Choice Research Partner, Aimia Pet HealthCo Inc., Signs Second R&D Partnership Agreement with KGK Science for Development of GLP1 Supplement…

By Global News Feed

TAMPA, Fla., Nov. 16, 2023 (GLOBE NEWSWIRE) -- Better Choice Company (NYSE: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, today announced its research partner, Aimia Pet HealthCo. Inc. (APH), has signed a memorandum of understanding (MOU) with KGK Science Inc. (KGK) for the development of a GLP1 supplement for pets.

Read the original post:
Better Choice Research Partner, Aimia Pet HealthCo Inc., Signs Second R&D Partnership Agreement with KGK Science for Development of GLP1 Supplement...

Gradalis Awarded $9.9 Million Grant From the Cancer Prevention and Research Institute of Texas

By Global News Feed

DALLAS, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Gradalis, Inc., a leader in the development of personalized anti-cancer cellular therapies for patients with solid tumors, announced today that it has been awarded a $9.9 million Product Development Research grant from the Cancer Prevention and Research Institute of Texas (CPRIT). The funds will be used to support the company's Phase 2 clinical study of Vigil® in platinum-sensitive patients who have recurrent ovarian cancer with a homologous recombination proficient (HRP) molecular profile. These patients face an acutely high unmet medical need due to the removal of PARP inhibitor therapies in 2022. The study is designed as a pivotal trial to confirm the positive survival results seen in ovarian cancer patients with the HRP profile tumors in Gradalis’ earlier VITAL study in frontline maintenance therapy. The company intends to pursue accelerated approval based on positive results.

Originally posted here:
Gradalis Awarded $9.9 Million Grant From the Cancer Prevention and Research Institute of Texas

Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers

By Global News Feed

Myriad expands pharma service offering by introducing Personalis’ ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx cancer tests Myriad expands pharma service offering by introducing Personalis’ ImmunoID NeXT® platform to its pharmaceutical partners who use MyRisk® Hereditary Cancer Test, BRACAnalysis CDx® and/or MyChoice® CDx cancer tests

See the original post here:
Myriad Genetics and Personalis Partner to Market Solutions to Pharma Customers

GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023

By Global News Feed

Lille (France), Cambridge (Massachusetts, United States), Zurich (Switzerland), November 16, 2023 – GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and life-threatening liver diseases, today announced the highlights from its “ACLF Day” held on November 11, 2023 during AASLD The Liver Meeting ® in Boston, MA (USA).

Read the rest here:
GENFIT Highlights ACLF Development Strategy at “ACLF Day” during AASLD The Liver Meeting® 2023

Polaris Group Initiates Rolling Submission of Biologic License Application (BLA) for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma

By Global News Feed

TAIPEI, Taiwan and SAN DIGEO, Nov. 16, 2023 (GLOBE NEWSWIRE) -- Polaris Group (The Company, TWSE:6550), today announced that the Company has initiated the rolling submission of its Biologic License Application (BLA) for ADI-PEG 20 to the U.S. Food and Drug Administration (FDA) for the systemic treatment of patients with malignant pleural mesothelioma with non-epithelioid histology, in combination with a platinum agent and pemetrexed. This submission is based on the results of the successful phase 3 trial of ADI-PEG 20 in combination with a platinum agent and pemetrexed which met both its primary and secondary objectives for progression free survival and overall survival. The rolling submission process allows for the submission of individual modules of the BLA as they are completed, which can streamline the regulatory review process and may expedite the potential approval timeline.

Original post:
Polaris Group Initiates Rolling Submission of Biologic License Application (BLA) for ADI-PEG 20 with U.S. FDA to Treat Malignant Pleural Mesothelioma

→←